{"filing":{"accession_number":"0001828316-26-000041","cik":"0001828316","ticker":"PHAR","company_name":"Pharming Group N.V.","form":"6-K","filing_date":"2026-09-25","report_date":"2026-09-25","primary_document":"pharmingannouncesusfdaacce.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828316/000182831626000041/pharmingannouncesusfdaacce.htm"},"events":[{"id":35059,"run_id":32286,"accession_number":"0001828316-26-000041","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces FDA acceptance and Priority Review of a supplemental New Drug Application (sNDA) for lower doses of Joenja® (leniolisib) to treat children with APDS, with a PDUFA target action date of January 30, 2027. This is a material regulatory milestone for a rare disease therapeutic that expands the eligible patient population and represents significant progress toward broadening commercial access. While not a discrete event type like M\u0026A or earnings, it is a material operational/regulatory development that would affect a reasonable investor's assessment of the company's pipeline and commercial prospects.","company_name":"Pharming Group N.V.","ticker":"PHAR","filing_date":"2026-09-25","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":38985,"accession_number":"0001828316-26-000041","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA acceptance and Priority Review of a supplemental New Drug Application (sNDA) for lower doses of Joenja® (leniolisib) to treat children with APDS, with a PDUFA target action date of January 30, 2027. This is a material regulatory milestone for a rare disease therapeutic that expands the eligible patient population and represents significant progress toward broadening commercial access. While not a discrete event type like M\u0026A or earnings, it is a material operational/regulatory development that would affect a reasonable investor's assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-25T15:13:52.965460+00:00","company_name":"Pharming Group N.V.","ticker":"PHAR","filing_date":"2026-09-25"}]}